HDAC inhibitors in leukemia: Current status and perspectives

Leukemia Research

Volumn 33, Issue 2, 2009, Pages 207-208

  Kouraklis, Gregory ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUTYRIC ACID; CYTARABINE; DNA METHYLTRANSFERASE INHIBITOR; ETOPOSIDE; HISTONE DEACETYLASE INHIBITOR; RETINOIC ACID; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG DOSE COMPARISON; EDITORIAL; GENETIC TRANSCRIPTION; HUMAN; LEUKEMIA CELL LINE; LOW DRUG DOSE; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HISTONE DEACETYLASES; HUMANS; LEUKEMIA;

EID: 56949086914     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.07.022     Document Type: Editorial

References (14)

1. Kouraklis G., and Theocharis S. Histone deacetylase inhibitors: a novel target of anticancer therapy. Oncol Rep 15 2 (2006) 489-494
2. Konstantopoulos P.A., Karamouzis M.V., and Papavassiliou A.G. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond. Expert Opin Invest Drugs 16 (2007) 569-571
3. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6 (2006) 38-51
4. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1 (2002) 287-299
5. Peart M.J., et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102 (2005) 3697-3702
6. Acharya M.R., et al. Rational development of histone deacetylase inhibitor as anticancer agents: a review. Mol Pharmacol 68 (2005) 917-932
7. Minucci S., et al. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?. Oncogene 20 (2001) 3110-3115
8. Kuendgen A., and Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer 110 (2007) 943-954
9. Glaser K.B. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 74 (2007) 659-671
10. Soriano A.O., et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukaemia and myelodysplastic syndrome. Blood 110 (2007) 2302-2308
11. Dos Santos M.P., Schwartsmann G., Roesler R., Brunetto A.L., and Abujamra A.L. Sodium butyrate enhances the cytotoxic effect of antineoplastic drugs in human lymphoblastic T-cells. Leuk Res 33 (2009) 218-221
12. Bhalla K.N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23 (2005) 3971-3993
13. Morphy R., and Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 48 (2005) 6523-6543
14. Saltz L.B., et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 25 (2007) 4793-4799